Logo image of CNTB

CONNECT BIOPHARMA HOLDINGS L (CNTB) Stock Fundamental Analysis

NASDAQ:CNTB - Nasdaq - US2075231017 - ADR - Currency: USD

0.8701  +0.01 (+1.17%)

Fundamental Rating

2

Overall CNTB gets a fundamental rating of 2 out of 10. We evaluated CNTB against 571 industry peers in the Biotechnology industry. The financial health of CNTB is average, but there are quite some concerns on its profitability. CNTB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CNTB has reported negative net income.
In the past year CNTB has reported a negative cash flow from operations.
CNTB had negative earnings in each of the past 5 years.
CNTB had a negative operating cash flow in each of the past 5 years.
CNTB Yearly Net Income VS EBIT VS OCF VS FCFCNTB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -200M -400M -600M -800M -1B

1.2 Ratios

CNTB has a Return On Assets (-43.01%) which is comparable to the rest of the industry.
With a decent Return On Equity value of -46.94%, CNTB is doing good in the industry, outperforming 67.20% of the companies in the same industry.
Industry RankSector Rank
ROA -43.01%
ROE -46.94%
ROIC N/A
ROA(3y)-61.15%
ROA(5y)-60.11%
ROE(3y)-68.95%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CNTB Yearly ROA, ROE, ROICCNTB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 50 -50

1.3 Margins

CNTB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNTB Yearly Profit, Operating, Gross MarginsCNTB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023

More info and screens

4

2. Health

2.1 Basic Checks

CNTB has about the same amout of shares outstanding than it did 1 year ago.
CNTB has more shares outstanding than it did 5 years ago.
CNTB has a worse debt/assets ratio than last year.
CNTB Yearly Shares OutstandingCNTB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
CNTB Yearly Total Debt VS Total AssetsCNTB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B

2.2 Solvency

CNTB has an Altman-Z score of -3.35. This is a bad value and indicates that CNTB is not financially healthy and even has some risk of bankruptcy.
CNTB has a Altman-Z score (-3.35) which is comparable to the rest of the industry.
CNTB has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
CNTB has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.35
ROIC/WACCN/A
WACCN/A
CNTB Yearly LT Debt VS Equity VS FCFCNTB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 1B -1B 2B

2.3 Liquidity

CNTB has a Current Ratio of 12.04. This indicates that CNTB is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CNTB (12.04) is better than 84.31% of its industry peers.
A Quick Ratio of 12.04 indicates that CNTB has no problem at all paying its short term obligations.
CNTB has a Quick ratio of 12.04. This is amongst the best in the industry. CNTB outperforms 84.31% of its industry peers.
Industry RankSector Rank
Current Ratio 12.04
Quick Ratio 12.04
CNTB Yearly Current Assets VS Current LiabilitesCNTB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

More info and screens

1

3. Growth

3.1 Past

CNTB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 92.21%, which is quite impressive.
EPS 1Y (TTM)92.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CNTB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.50% yearly.
Based on estimates for the next years, CNTB will show a very negative growth in Revenue. The Revenue will decrease by -19.61% on average per year.
EPS Next Y73.94%
EPS Next 2Y26.57%
EPS Next 3Y16.08%
EPS Next 5Y14.5%
Revenue Next Year15.06%
Revenue Next 2Y36.57%
Revenue Next 3Y6.69%
Revenue Next 5Y-19.61%

3.3 Evolution

CNTB Yearly Revenue VS EstimatesCNTB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
CNTB Yearly EPS VS EstimatesCNTB Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10 -15 -20 -25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CNTB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CNTB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CNTB Price Earnings VS Forward Price EarningsCNTB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNTB Per share dataCNTB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

CNTB's earnings are expected to grow with 16.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.57%
EPS Next 3Y16.08%

More info and screens

0

5. Dividend

5.1 Amount

CNTB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CONNECT BIOPHARMA HOLDINGS L

NASDAQ:CNTB (2/21/2025, 8:10:26 PM)

0.8701

+0.01 (+1.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-15 2024-04-15/amc
Earnings (Next)N/A N/A
Inst Owners44.85%
Inst Owner Change-96.96%
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap48.08M
Analysts82.86
Price Target8.16 (837.82%)
Short Float %0.1%
Short Ratio1.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)14.29%
PT rev (3m)14.29%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-8.79%
EPS NY rev (3m)-8.79%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)1.12%
Revenue NY rev (3m)1.12%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.99
P/FCF N/A
P/OCF N/A
P/B 0.44
P/tB 0.44
EV/EBITDA N/A
EPS(TTM)-0.95
EYN/A
EPS(NY)-2.4
Fwd EYN/A
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.45
OCFYN/A
SpS0.44
BVpS2
TBVpS2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -43.01%
ROE -46.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.15%
ROA(5y)-60.11%
ROE(3y)-68.95%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 46.08%
Cap/Sales 1.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.04
Quick Ratio 12.04
Altman-Z -3.35
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)357.04%
Cap/Depr(5y)452.35%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125.9%
EPS Next Y73.94%
EPS Next 2Y26.57%
EPS Next 3Y16.08%
EPS Next 5Y14.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year15.06%
Revenue Next 2Y36.57%
Revenue Next 3Y6.69%
Revenue Next 5Y-19.61%
EBIT growth 1Y91.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y93.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y92.95%
OCF growth 3YN/A
OCF growth 5YN/A